Nuvation Bio Chief Regulatory Officer Buys 50,000 Shares at $1.80

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), reported significant insider purchases on June 16, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), reported significant insider purchases on June 16, 2025. The transactions involved:

First purchase: 26,000 shares of Class A Common Stock at $1.79 per share
Second purchase: 24,000 shares of Class A Common Stock at $1.80 per share

Following these transactions, Wentworth directly owns a total of 50,000 shares of Class A Common Stock. The insider's substantial purchase of shares, totaling approximately $89,740, could signal confidence in the company's future prospects. The Form 4 was filed through an attorney-in-fact, Stephen Dang, on June 18, 2025.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 2 txns

Insider Wentworth Kerry

Role CHIEF REGULATORY OFFICER

Bought 50,000 shs ($90K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	26,000	$1.79	$47K
Purchase	Class A Common Stock	24,000	$1.80	$43K

Holdings After Transaction: Class A Common Stock — 50,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of NUVB stock did Chief Regulatory Officer Kerry Wentworth purchase on June 16, 2025?

Kerry Wentworth purchased a total of 50,000 shares of NUVB Class A Common Stock on June 16, 2025, split into two transactions: 26,000 shares at $1.79 per share and 24,000 shares at $1.80 per share.

What was the total value of NUVB insider purchase by Kerry Wentworth in June 2025?

The total value of Kerry Wentworth's purchase was approximately $89,740, calculated from 26,000 shares at $1.79 ($46,540) plus 24,000 shares at $1.80 ($43,200).

What position does Kerry Wentworth hold at NUVB?

Kerry Wentworth serves as the Chief Regulatory Officer at Nuvation Bio Inc. (NUVB).

How many NUVB shares does Kerry Wentworth own after the June 16, 2025 purchases?

Following the reported transactions, Kerry Wentworth directly owns 50,000 shares of NUVB Class A Common Stock.

Was NUVB insider Kerry Wentworth's stock purchase made under a 10b5-1 trading plan?

No, the Form 4 filing does not indicate that the transactions were made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox was not marked on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2025 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wentworth Kerry

(Last)

(First)

(Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF REGULATORY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/16/2025		P		26,000	A	$1.79	26,000	D
Class A Common Stock	06/16/2025		P		24,000	A	$1.8	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Stephen Dang, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR